Amgen is raising its outlook after beating earnings and dropping a weight loss drug

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

Retatrutide — also known as "reta" — has been shown to produce dramatically greater weight loss than Ozempic and Mounjaro.

Eli Lilly’s chief executive David Ricks told investors that it was ‘building for the future’

International research suggests losing weight may help people get a job - and their New Zealand counterparts say it can't be ruled out here, either.

Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug, retatrutide, which has not been approved yet by the FDA. The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years. Dr. Rachel Pessah Pollack discusses what we know about its safet

A breast cancer surgeon explains how GLP-1 drugs like Ozempic and Wegovy may lower cancer recurrence risk by reducing BMI, estrogen and inflammation.

Eli Lilly to offer early access to next-gen obesity drug to some patients  Reuters

Doctors are asking how to get retatrutide for their patients, after Eli Lilly gave one man early access.

Jaime says TikTok taught her how to buy and inject black market peptides. Months later, she had lost 17kg.

"Employers are dropping coverage for GLP-1 drugs like Wegovy and Zepbound in greater numbers, nudging more patients to direct-to-consumer prescriptions."